Latest news with #VeevaSystems
Yahoo
02-08-2025
- Business
- Yahoo
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
Veeva Systems VEEV is leaning heavily on its Vault R&D platform to anchor long-term growth, and so far, it's working. The platform, which spans clinical, regulatory, quality, and safety domains, continues to see healthy customer expansion and product adoption. In its latest update, management highlighted strength in areas like Vault Safety and Vault Clinical, where digitization and automation are reshaping how trials are run and managed. Veeva's deep relationships with top pharma clients, combined with ongoing investments in domain-specific AI, are helping it evolve from a software vendor into a strategic infrastructure partner across the drug development lifecycle. Still, the landscape is changing. AI-native challengers are emerging with new ways to approach trial design, drug safety monitoring and data workflows. While Veeva is embedding AI across its R&D suite, supporting functions like regulatory document drafting and case processing, it's now competing not only with traditional players, but also with younger, more specialized platforms. The company's scale, focus on compliance, and integration depth remain strong differentiators, but investors will want to see continued innovation and proof that Veeva can hold its lead in an increasingly dynamic and data-driven market. Peers Update A name to watch in this space is Dassault Systemes DASTY, which operates Medidata, a major provider of cloud-based solutions for clinical trials. Medidata is expanding its capabilities through AI-powered tools for trial planning and patient recruitment. While its approach differs from Veeva's, both companies are addressing similar challenges in trial efficiency and data quality. Dassault also brings strength in simulation and manufacturing through its broader 3DEXPERIENCE platform, offering customers a more holistic lens on product development. Another adjacent player is Schrodinger Inc. SDGR, known for its AI-driven drug discovery platform. While Schrödinger operates earlier in the R&D value chain, its traction with biopharma clients reflects the growing demand for specialized, cloud-first tools in life sciences. As R&D organizations diversify their tech stacks, companies like Schrödinger could complement, not necessarily compete with, platforms like Veeva, particularly in environments where speed and innovation are prioritized. Veeva Systems' Price Performance, Valuation and Estimates Shares of VEEV have gained 35.4% in the year-to-date period compared with the industry's growth of 10.7%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.2, above the industry average. VEEV carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dassault Systemes SA (DASTY) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Schrodinger, Inc. (SDGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
02-08-2025
- Business
- Yahoo
Veeva Systems (VEEV) Stock Moves -1.09%: What You Should Know
In the latest trading session, Veeva Systems (VEEV) closed at $281.11, marking a -1.09% move from the previous day. The stock's change was more than the S&P 500's daily loss of 1.6%. On the other hand, the Dow registered a loss of 1.23%, and the technology-centric Nasdaq decreased by 2.24%. The stock of provider of cloud-based software services for the life sciences industry has fallen by 0.03% in the past month, leading the Medical sector's loss of 3.44% and undershooting the S&P 500's gain of 2.25%. The investment community will be paying close attention to the earnings performance of Veeva Systems in its upcoming release. The company's upcoming EPS is projected at $1.9, signifying a 17.28% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $767.61 million, up 13.52% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $7.64 per share and revenue of $3.1 billion, indicating changes of +15.76% and +12.78%, respectively, compared to the previous year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Veeva Systems. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Veeva Systems is currently sporting a Zacks Rank of #3 (Hold). With respect to valuation, Veeva Systems is currently being traded at a Forward P/E ratio of 37.18. Its industry sports an average Forward P/E of 26.27, so one might conclude that Veeva Systems is trading at a premium comparatively. Meanwhile, VEEV's PEG ratio is currently 1.6. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 2.78. The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 56, placing it within the top 23% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
30-07-2025
- Business
- Yahoo
Survey Finds Medtechs Lack Confidence in Regulatory Data Quality
Veeva MedTech report reveals opportunity to move beyond manual processes for speed and compliance PLEASANTON, Calif., July 30, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced findings from the 2025 Veeva Medtech Regulatory Affairs Benchmark, revealing that 50% of respondents lack full confidence in the completeness of their underlying data for global product registrations. Many organizations are manually reconciling data to ensure regulatory compliance, increasing the administrative burden for regulatory affairs teams. With the rise of new technology to streamline and automate regulatory processes, high data quality is paramount for medtech innovation. When considering effective AI implementation, only 17% rate their regulatory data quality as excellent, with the remainder categorizing it as average or worse. The report from Veeva MedTech examines the current state of regulatory operations, including: Lengthy timelines for submission preparation. From data gathering to internal approval, preparing a submission for a 510(k) takes a month or longer for 80% of respondents, with 24% indicating that it takes more than six months. With organizations spending up to two years on each MDR submission, medtechs that reduce submission timelines can get products to market faster with considerable cost and resource savings. Prioritizing time to market measurement. Only 5% of those surveyed use a fully automated process to monitor time to market, a key metric for effective resource planning. About two-thirds (67%) partially or entirely rely on manual processes, making it difficult to generate accurate and timely performance insights. Room for regulatory operational improvement. Respondents identified heavy administrative burden (61%), siloed processes (49%), digital tool proficiency (35%), and educational shortcomings (24%) as the largest gaps in regulatory affairs, all of which may hinder product registrations and slow time to market. Technology advancing regulatory affairs. More organizations are making strategic decisions to improve efficiency and compliance, with 56% planning to adopt a regulatory information management (RIM) system. Nearly half of respondents are looking to develop integrations between existing systems (52%) or implement automated submission tracking and reporting tools (48%) to gain unified, accessible data. "The report illustrates key areas to evolve regulatory affairs to a strategic enabler of business objectives through connected, automated processes for increased data reliability and speed," says Seth Goldenberg, president, Veeva MedTech. "As teams are asked to do more with the same resources, addressing operational gaps to foster agility while maintaining compliance in the evolving regulatory landscape will be critical." The 2025 Medtech Regulatory Affairs Benchmark surveyed a diverse group of 130 regulatory professionals, exploring the most critical challenges facing regulatory teams today. To learn more, read the full benchmark report here. About Veeva MedTech Veeva MedTech helps medical device and diagnostics companies streamline the complete product development and commercialization lifecycles to deliver products to patients with greater speed and efficiency. Veeva MedTech's offering includes applications that advance clinical, regulatory, quality, commercial, and medical operations. For more information, visit About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-Looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact:Deivis MercadoVeeva View original content to download multimedia: SOURCE Veeva Systems Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
28-07-2025
- Business
- Yahoo
Veeva Systems (VEEV) Surpassed Expectations in Q2
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Mid Cap Composite returned 3.46% net-of-fees in the quarter, trailing the Russell Mid Cap Growth Index's 18.20% return. After a strong first quarter in 2025, investor enthusiasm shifted towards high-beta and AI stocks following the "Liberation Day" announcements, creating a narrow leadership group that posed challenges for the Mid Cap Strategy in the second quarter. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Veeva Systems Inc. (NYSE:VEEV). Veeva Systems Inc. (NYSE:VEEV) offers cloud-based software for the life sciences industry. The one-month return of Veeva Systems Inc. (NYSE:VEEV) was 0.84%, and its shares gained 51.52% of their value over the last 52 weeks. On July 25, 2025, Veeva Systems Inc. (NYSE:VEEV) stock closed at $290.41 per share, with a market capitalization of $47.456 billion. Conestoga Capital Advisors stated the following regarding Veeva Systems Inc. (NYSE:VEEV) in its second quarter 2025 investor letter: "Veeva Systems Inc. (NYSE:VEEV) is a vertical SaaS company for the life sciences industry with a wide range of integrated cloud-based software applications and services. VEEV reported a strong start to their fiscal year, materially outperforming expectations across the board. The company added 28 new Vault CRM customers during the quarter, marking over 80 customers live vs. only a handful a year ago. Additionally, VEEV now expects about 200 Vault CRM customers by next year." A team of IT experts monitoring a network of computers managing the medical content and communications. Veeva Systems Inc. (NYSE:VEEV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held Veeva Systems Inc. (NYSE:VEEV) at the end of the first quarter, which was 60 in the previous quarter. The first quarter marked a solid beginning for Veeva Systems Inc. (NYSE:VEEV), with results surpassing expectations. The total revenue for the quarter reached $759 million, and the non-GAAP operating margin remained robust. While we acknowledge the potential of Veeva Systems Inc. (NYSE:VEEV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Veeva Systems Inc. (NYSE:VEEV) and shared the list of best cloud stocks to buy according to Wall Street analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
28-07-2025
- Business
- Yahoo
Veeva Systems (VEEV) Surpassed Expectations in Q2
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Mid Cap Composite returned 3.46% net-of-fees in the quarter, trailing the Russell Mid Cap Growth Index's 18.20% return. After a strong first quarter in 2025, investor enthusiasm shifted towards high-beta and AI stocks following the "Liberation Day" announcements, creating a narrow leadership group that posed challenges for the Mid Cap Strategy in the second quarter. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Veeva Systems Inc. (NYSE:VEEV). Veeva Systems Inc. (NYSE:VEEV) offers cloud-based software for the life sciences industry. The one-month return of Veeva Systems Inc. (NYSE:VEEV) was 0.84%, and its shares gained 51.52% of their value over the last 52 weeks. On July 25, 2025, Veeva Systems Inc. (NYSE:VEEV) stock closed at $290.41 per share, with a market capitalization of $47.456 billion. Conestoga Capital Advisors stated the following regarding Veeva Systems Inc. (NYSE:VEEV) in its second quarter 2025 investor letter: "Veeva Systems Inc. (NYSE:VEEV) is a vertical SaaS company for the life sciences industry with a wide range of integrated cloud-based software applications and services. VEEV reported a strong start to their fiscal year, materially outperforming expectations across the board. The company added 28 new Vault CRM customers during the quarter, marking over 80 customers live vs. only a handful a year ago. Additionally, VEEV now expects about 200 Vault CRM customers by next year." A team of IT experts monitoring a network of computers managing the medical content and communications. Veeva Systems Inc. (NYSE:VEEV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held Veeva Systems Inc. (NYSE:VEEV) at the end of the first quarter, which was 60 in the previous quarter. The first quarter marked a solid beginning for Veeva Systems Inc. (NYSE:VEEV), with results surpassing expectations. The total revenue for the quarter reached $759 million, and the non-GAAP operating margin remained robust. While we acknowledge the potential of Veeva Systems Inc. (NYSE:VEEV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Veeva Systems Inc. (NYSE:VEEV) and shared the list of best cloud stocks to buy according to Wall Street analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
